Violet Mukaro

ORCID: 0000-0002-3968-6551
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Breast Cancer Treatment Studies
  • Phagocytosis and Immune Regulation
  • Galectins and Cancer Biology
  • Immune Response and Inflammation
  • Cancer Treatment and Pharmacology
  • HER2/EGFR in Cancer Research
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Neonatal Respiratory Health Research
  • Pediatric health and respiratory diseases
  • Immune Cell Function and Interaction
  • Immune cells in cancer
  • NF-κB Signaling Pathways
  • Emergency and Acute Care Studies
  • interferon and immune responses
  • Exercise and Physiological Responses
  • Cancer Genomics and Diagnostics
  • Statistical Methods in Clinical Trials
  • Medical Imaging Techniques and Applications
  • Cholesterol and Lipid Metabolism
  • Genomics, phytochemicals, and oxidative stress
  • Macrophage Migration Inhibitory Factor
  • Healthcare Decision-Making and Restraints
  • Rabies epidemiology and control
  • Cell death mechanisms and regulation
  • Inhalation and Respiratory Drug Delivery

Royal Adelaide Hospital
2011-2021

The University of Melbourne
2020-2021

Deakin University
2016-2019

Geelong Hospital
2017-2019

Women's and Children's Hospital
2011-2018

South Australia Pathology
2011-2018

Barwon Health
2014-2016

Hanson Institute
2011-2014

The University of Adelaide
2008-2011

Women's and Children's Health Network
2008-2010

Section:ChooseTop of pageAbstract <<MATERIALS AND METHODSRESULTSDISCUSSIONReferencesCITING ARTICLES

10.1165/rcmb.2009-0459oc article EN American Journal of Respiratory Cell and Molecular Biology 2010-07-02

Our previous studies have shown that nutritional zinc restriction exacerbates airway inflammation accompanied by an increase in caspase-3 activation and accumulation of apoptotic epithelial cells the bronchioles mice. Normally, are rapidly cleared macrophage efferocytosis, limiting any secondary necrosis inflammation. We therefore hypothesized deficiency is not only pro-apoptotic but also impairs efferocytosis. Impaired efferocytic clearance alveolar macrophages occurs chronic obstructive...

10.1371/journal.pone.0110056 article EN cc-by PLoS ONE 2014-10-28

Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease; it leading cause of death and existing treatments have no proven disease-modifying effect. The mechanisms underlying this resistance are largely unknown, but suggest the presence some self-maintaining pathogenic process, possibly initiated by cigarette smoking, that prevents normal resolution inflammation. We previously reported increased production proinflammatory cytokines granzyme b CD8(+) T cells in...

10.1111/j.1365-2249.2011.04455.x article EN Clinical & Experimental Immunology 2011-07-05

Natural killer (NK) and natural T (NKT)-like cells represent a small but important proportion of effector lymphocytes that we have previously shown to be major sources pro-inflammatory cytokines granzymes. We hypothesized these would increased in the airway chronic obstructive pulmonary disease (COPD), accompanied by reduced expression inhibitory receptor CD94 (Kp43) cytotoxic mediators granzyme B perforin.We measured NK NKT-like their blood COPD patients (n = 71; 30 current 41 ex-smokers),...

10.1111/j.1440-1843.2012.02287.x article EN Respirology 2012-10-15

We have previously shown that the defective ability of alveolar macrophages (AM) to phagocytose apoptotic cells ('efferocytosis') in chronic obstructive pulmonary disease/emphysema (COPD) could be therapeutically improved using C-type lectin, mannose binding lectin (MBL), although exact mechanisms underlying this effect are unknown. An S-type galectin-3, is also known regulate macrophage phenotype and function, via interaction with its receptor CD98. hypothesized expression galectin/CD98...

10.1371/journal.pone.0056147 article EN cc-by PLoS ONE 2013-02-18

Abstract In chronic obstructive pulmonary disease (COPD) apoptotic bronchial epithelial cells are increased, and their phagocytosis by alveolar macrophages (AM) is decreased alongside bacterial phagocytosis. Epithelial cellular lipids, including those exposed on uncleared bodies, can become oxidized, may be recognized presented as non-self antigen presenting cells. CD1b a lipid-presenting protein, previously only described in dendritic We investigated whether upregulated COPD AM, lipid...

10.1038/s41598-021-82481-0 article EN cc-by Scientific Reports 2021-02-18

While consumption of omega-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA) has been recommended for those at risk inflammatory disease such as rheumatoid arthritis, the mechanism their anti-inflammatory effect remains to be clearly defined, particularly in relation dose and type n-3 LCPUFA. The objective this study was determine whether varying levels LCPUFA erythrocyte membrane lipids, following dietary supplementation, is associated with altered numbers function circulating...

10.1186/ar2426 article EN cc-by Arthritis Research & Therapy 2008-01-01

Despite anti-TNF therapy advancements for inflammatory diseases such as rheumatoid arthritis, the burden of remains high. An 11-mer TNF peptide, TNF70-80, is known to stimulate selective functional responses compared parent molecule. Here, we show that TNF70-80 binds receptor, activating p38 MAP kinase through receptor-associated factor 2. Using truncated TNFR mutants, identify sequence in TNFRI which enables activation by TNF70-80. Peptides with this sequence, TNFRI206-211 bind and inhibit...

10.1038/s41467-018-03640-y article EN cc-by Nature Communications 2018-04-04

In chronic obstructive pulmonary disease (COPD/emphysema) we have shown a reduced ability of lung and alveolar (AM) macrophages to phagocytose apoptotic cells (defective ‘efferocytosis’), associated with evidence secondary cellular necrosis resultant inflammatory response in the airway. It is unknown whether this defect present cancer (no COPD) if so, results from soluble mediators produced by cells. We investigated efferocytosis AM (26 controls, 15 healthy smokers, 37 COPD, 20 COPD+ non...

10.1371/journal.pone.0061573 article EN cc-by PLoS ONE 2013-04-26

Abstract Objective Patients diagnosed with cancer in the E mergency D epartment ( ED ) have more advanced disease at diagnosis and poorer outcomes. High rates of initial presentation to suggest potential problems access care. The aim this project was interpret findings regional/rural Victoria explore implications for practice. Design Cross‐sectional study linking two independent data sets. Setting Regional city G eelong surrounding rural areas south‐west V ictoria. Participants All newly...

10.1111/ajr.12280 article EN Australian Journal of Rural Health 2016-02-02

Background This study evaluated the feasibility of achieving high response rates in stage II or III breast cancer by tailoring neoadjuvant therapy using clinical and histopathological features Oncotype DX Breast Recurrence Score. Genomic determinants resistance were also explored. Patients outcome measures Fifty-one patients enrolled. The primary cohort comprised 40 patients: 15 human epidermal growth factor receptor type 2 (HER2)-amplified; triple-negative (TNBC); ten hormone (HR)-positive,...

10.1371/journal.pone.0210891 article EN cc-by PLoS ONE 2019-02-14

Abstract JNK is identified as a key MAP kinase which regulates neutrophil bactericidal activity and chemotaxis. The role of in chemotaxis killing microbial pathogens remains unclear. Using recently described cell-permeable peptide inhibitor the pathway, based on JBD JIP-1, coupled to protein transduction domain HIV-TAT (TAT-JIP), association with control peptides, we demonstrate that pathway plays major regulating human pathogens. Serum-opsonized Staphylococcus aureus elicited activation...

10.1189/jlb.0609399 article EN Journal of Leukocyte Biology 2010-01-22

Magnetic resonance imaging (MRI) accuracy after neoadjuvant systemic therapy (NST) for breast cancer varies according to hormone receptor (HR), human epidermal growth factor type-2 (HER2) subtype and Ki-67 proliferation index. Whether MRI by genomic signatures is unknown. We examined the of in NEONAB trial (Clinicaltrials.gov #: NCT01830244).To examine predict pathological response trial.Patients with stages II-III received sequential epirubicin, cyclophosphamide nab-paclitaxel trastuzumab...

10.1111/imj.13617 article EN Internal Medicine Journal 2017-09-04

10.2174/1389210204504764501 article EN Current Drug Targets 2010-07-29

Abstract Behavioural assessment units (BAU) have been established in emergency departments (EDs) to provide short‐term observation, treatment, and care people experiencing acute behavioural disturbance. A prospective observational study was conducted a cohort of adult patients admitted one BAU located within an ED (July–December 2017) compare clinical characteristics, treatment outcomes, use restrictive interventions for those who received specialist mental health (MH) with did not. Of the...

10.1111/inm.12779 article EN International Journal of Mental Health Nursing 2020-09-14

Despite recent reviews of best practice for the treatment Australian venomous bites and stings, there is controversy about some aspects care, particularly use antivenom. Our aim was to understand current attitudes in management suspected snake envenoming. A single-stage, cross-sectional survey emergency care physicians who had treated envenomation previous 36 months conducted. Hospital pharmacists were also invited complete a antivenom availability, usage, wastage hospitals. The available...

10.3390/toxins13070482 article EN cc-by Toxins 2021-07-12

TPS1135 Background: Neoadjuvant chemotherapy for breast cancer allows response to be assessed depending on subtype, and judge impact of therapy progression-free survival (PFS). Methods: This study enrols women with tumours > 2cm high likelihood response, receive Epirubicin 90mg/m2 Cyclophosphamide 600mg/m2 Q3 weeks x 4 followed by nab-Paclitaxel (125mg/m2 IV days 1, 8, 15 Q4 weeks) 12 weeks. Trastuzumab weeks, will added nab-paclitaxel in HER2 positive patients. Forty women; positive, triple...

10.1200/jco.2014.32.15_suppl.tps1135 article EN Journal of Clinical Oncology 2014-05-20

e12025 Background: We evaluated tailored neoadjuvant chemotherapy (NAC) with sequential EC followed by nab-Paclitaxel. OncotypeDX assay was used to select women Hormone Receptor (HR) + early BC. Methods: Between 4/2013 and 1/2015, patients stage II (T > 2cm) or III BC received Epirubicin 90mg/m2 Cyclophosphamide 600mg/m2 Q3 weeks x 4, nab-Paclitaxel (125mg/m2 IV days 1, 8, 15 Q4 weeks) for 12 weeks. Trastuzumab added nab-paclitaxel in HER2+ patients. The primary cohort consisting of forty...

10.1200/jco.2015.33.15_suppl.e12025 article EN Journal of Clinical Oncology 2015-05-20
Coming Soon ...